THE ELITE TEST BANK:
PRIMARY CARE
INTERPROFESSIONAL
COLLABORATIVE PRACTICE
PART I: THE PRIMER
Mastering interprofessional collaborative practice (IPCP) is the singular determinant of clinical
leadership in the 2026/2027 healthcare landscape. This gauntlet shifts the focus from rote
memorization to high-stakes professional intuition, ensuring the practitioner navigates the
convergence of AI integration, value-based reimbursement, and health equity with surgical
precision.
The Panic Button Cheat Sheet
Domain 2026/2027 Professional Mandate
Metabolic Care 5–7% weight loss target; GLP-1 RA for HFpEF
and MASH; A1C <7.0%
Digital Billing 10-minute RPM threshold (99457); 2–15 day
data capture; POS 10 for home
Renal Integrity CKD-EPI 2021 Race-Free eGFR; Cystatin C for
Stage 3 confirmation
Opioid Safety 50 MME reassessment; 90 MME hard alert;
3-day acute limit; Gabapentinoid warning
PART II: THE ELITE TEST BANK
Foundational Syntax & Application (Questions 1–15)
Q1: A primary care practice is restructuring its workflow to align with the
Interprofessional Education Collaborative (IPEC) Core Competencies Version 3 (2023).
When the team establishes a protocol for managing ethical dilemmas in
cross-disciplinary care, which sub-competency within the "Values and Ethics" domain
are they primarily operationalizing? A) Implementing a strictly hierarchical decision-making
tree led by the senior physician. B) Working with individuals of other professions to maintain a
climate of mutual respect and shared values. C) Assigning profit-sharing quotas based on
individual productivity metrics. D) Utilizing a software-driven clinical decision support system to
automate ethical resolutions.
● The Answer: B) Working with individuals of other professions to maintain a climate of
mutual respect and shared values.
, ● Distractor Analysis: Option A is an archaic "siloed" approach that IPEC Version 3
explicitly aims to replace with collaborative leadership. Option C focuses on the
"Transactional Aim" rather than the "Quintuple Aim" of clinical excellence and health
equity. Option D is a dangerous over-reliance on technology that abdicates the
professional's ethical responsibility to the patient.
● The Mentor's Analysis: In the 2026/2027 clinical environment, "Values and Ethics" is not
a passive concept; it is an active, team-based behavior. The update to Version 3
emphasizes that ethical conduct must be a "coherent team endeavor" rather than the
independent responsibility of a single discipline. As a Lead Practitioner, your intuition must
recognize that a failure in mutual respect is a primary root cause of diagnostic error and
patient safety lapses. Collaboration is the structural framework upon which all 228
chapters of Buttaro’s collaborative practice are built.
Q2: The 2026 ADA Standards of Care have revised the criteria for obesity management in
patients with Type 2 Diabetes. For a patient currently at a Body Mass Index (BMI) of 33,
what is the specific weight loss target recommended to trigger significant metabolic
improvement and potential disease remission? A) 2% to 3% of baseline body weight. B) At
least 5% to 7% of baseline body weight. C) A minimum of 20% of baseline body weight before
pharmacological intervention. D) Returning to a "normal" BMI of 24.9 within the first six months
of diagnosis.
● The Answer: B) At least 5% to 7% of baseline body weight.
● Distractor Analysis: Option A is insufficient to achieve the physiological shifts in insulin
sensitivity required by the 2026 standards. Option C represents a legacy
"lifestyle-first-only" delay that the current standards have replaced with early, aggressive
pharmacotherapy (e.g., GLP-1 RAs). Option D is often clinically unattainable and focuses
on the "number" rather than the metabolic "function," which can lead to patient attrition
and psychological distress.
● The Mentor's Analysis: The 2026/2027 professional standard has moved away from the
"all-or-nothing" BMI approach toward incremental, evidence-based targets. A 5–7%
reduction is the "Hard Deck" for preventing the progression of pre-diabetes and improving
glycemic control in established Type 2 Diabetes. This reflects a shift in clinical register: we
no longer "encourage weight loss" generically; we "prescribe metabolic targets" with the
same precision as a statin or an ACE inhibitor.
Q3: A primary care coordinator is reviewing the 2026 CPT code updates for digital health.
Under the new guidelines, which code pair is used to report remote monitoring treatment
management when the clinical staff spends at least 10 minutes (but less than 20) during a
calendar month? A) 99457 and 99458. B) 99445 and 99470. C) 99213 and 99214. D) 98000
and 98008.
● The Answer: B) 99445 and 99470.
● Distractor Analysis: Option A refers to the legacy threshold of 20 minutes, which is now
considered "high-intensity" management. Option C contains standard E/M codes for
in-person visits. Option D refers to the new synchronous audio-video and audio-only
codes for telehealth encounters, not the longitudinal management of remote data.
● The Mentor's Analysis: The 2026 reduction of the management threshold from 20 to 10
minutes is a strategic pivot by CMS to reward "micro-interventions." As a professional,
you must understand that AI-augmented workflows allow your team to identify abnormal
heart rhythms or glucose spikes in seconds. If the billing structure stayed at 20 minutes, it
would penalize efficiency. Mastery of 99445/99470 allows your practice to remain
financially viable while providing the "continuous, preventive engagement" required to
, meet the 2027 standards for population health.
Q4: When calculating the estimated glomerular filtration rate (eGFR) for a 52-year-old
Black male patient presenting for his annual physical in 2027, which clinical protocol is
mandated by the NKF-ASN Task Force to ensure health equity? A) Use of the 2009 MDRD
equation with the race coefficient to avoid under-diagnosing. B) Use of the 2021 CKD-EPI
creatinine equation without a race coefficient. C) Exclusive use of the Cockcroft-Gault formula
for all drug dosing. D) Calculating eGFR based solely on the patient’s self-reported skin tone.
● The Answer: B) Use of the 2021 CKD-EPI creatinine equation without a race coefficient.
● Distractor Analysis: Option A is the "trap" of outdated practice; using a race coefficient
can falsely elevate eGFR results for Black patients, potentially delaying their referral for
kidney transplants or specialist care. Option C is used for some pharmacokinetic
modeling but is not the standard for staging chronic kidney disease (CKD). Option D is an
ethical and clinical absurdity that violates the "Island Rule" of biological precision.
● The Mentor's Analysis: The transition to race-free eGFR (CKD-EPI 2021) is a
non-negotiable professional standard in 2027. Race is a social, not a biological, construct.
By removing the coefficient, we ensure that every patient—regardless of ancestry—is
measured by the same metabolic yardstick. If the result is between 45 and 59
mL/min/1.73m² (Stage 3a), your next professional intuition should be to order a Cystatin C
test to calculate the eGFRcr-cys, which provides the highest level of accuracy for clinical
staging.
Q5: A patient with acute-onset low back pain presents to the clinic. The practitioner
identifies "saddle anesthesia" and new-onset urinary incontinence. According to the
Mahan Buttaro "Red Flag" highlights, what is the immediate required course of action?
A) Prescribe a 10-day course of high-dose NSAIDs and a muscle relaxant. B) Schedule an
outpatient MRI to be completed within the next 14 days. C) Initiate an "Emergency Referral" to
the nearest trauma center for suspected Cauda Equina Syndrome. D) Recommend bed rest
and a follow-up appointment in one month.
● The Answer: C) Initiate an "Emergency Referral" to the nearest trauma center for
suspected Cauda Equina Syndrome.
● Distractor Analysis: Option A treats the symptoms while ignoring a surgical emergency.
Option B is a dangerous delay; Cauda Equina requires intervention within hours, not
weeks, to prevent permanent paralysis. Option D is clinical negligence that would result in
a devastating professional crisis.
● The Mentor's Analysis: The "Red Flag" highlights in Buttaro's 6th and 7th editions are
"Not-to-be-Missed" signals. In the interprofessional environment, these are the triggers
that bypass the standard "wait-and-see" protocols. Professional intuition dictates that
when neurological function (bowel/bladder) is compromised, the primary care role shifts
from "Diagnostician" to "Emergency Coordinator." Your success as a Lead Practitioner is
defined as much by what you refer as what you treat.
Q6: In the 2026 ADA Standards of Care, the classification of MASLD (Metabolic
Dysfunction-Associated Steatotic Liver Disease) has been integrated into the diabetic
management algorithm. Which medication class is now preferred for glycemic
management in a patient with Type 2 Diabetes and biopsy-proven MASH (Metabolic
Dysfunction-Associated Steatohepatitis)? A) Sulfonylureas such as Glimepiride. B) GLP-1
Receptor Agonists (GLP-1 RAs) with demonstrated benefit. C) DPP-4 Inhibitors such as
Sitagliptin. D) Meglitinides.
● The Answer: B) GLP-1 Receptor Agonists (GLP-1 RAs) with demonstrated benefit.
● Distractor Analysis: Option A is weight-neutral or causes weight gain, providing no
PRIMARY CARE
INTERPROFESSIONAL
COLLABORATIVE PRACTICE
PART I: THE PRIMER
Mastering interprofessional collaborative practice (IPCP) is the singular determinant of clinical
leadership in the 2026/2027 healthcare landscape. This gauntlet shifts the focus from rote
memorization to high-stakes professional intuition, ensuring the practitioner navigates the
convergence of AI integration, value-based reimbursement, and health equity with surgical
precision.
The Panic Button Cheat Sheet
Domain 2026/2027 Professional Mandate
Metabolic Care 5–7% weight loss target; GLP-1 RA for HFpEF
and MASH; A1C <7.0%
Digital Billing 10-minute RPM threshold (99457); 2–15 day
data capture; POS 10 for home
Renal Integrity CKD-EPI 2021 Race-Free eGFR; Cystatin C for
Stage 3 confirmation
Opioid Safety 50 MME reassessment; 90 MME hard alert;
3-day acute limit; Gabapentinoid warning
PART II: THE ELITE TEST BANK
Foundational Syntax & Application (Questions 1–15)
Q1: A primary care practice is restructuring its workflow to align with the
Interprofessional Education Collaborative (IPEC) Core Competencies Version 3 (2023).
When the team establishes a protocol for managing ethical dilemmas in
cross-disciplinary care, which sub-competency within the "Values and Ethics" domain
are they primarily operationalizing? A) Implementing a strictly hierarchical decision-making
tree led by the senior physician. B) Working with individuals of other professions to maintain a
climate of mutual respect and shared values. C) Assigning profit-sharing quotas based on
individual productivity metrics. D) Utilizing a software-driven clinical decision support system to
automate ethical resolutions.
● The Answer: B) Working with individuals of other professions to maintain a climate of
mutual respect and shared values.
, ● Distractor Analysis: Option A is an archaic "siloed" approach that IPEC Version 3
explicitly aims to replace with collaborative leadership. Option C focuses on the
"Transactional Aim" rather than the "Quintuple Aim" of clinical excellence and health
equity. Option D is a dangerous over-reliance on technology that abdicates the
professional's ethical responsibility to the patient.
● The Mentor's Analysis: In the 2026/2027 clinical environment, "Values and Ethics" is not
a passive concept; it is an active, team-based behavior. The update to Version 3
emphasizes that ethical conduct must be a "coherent team endeavor" rather than the
independent responsibility of a single discipline. As a Lead Practitioner, your intuition must
recognize that a failure in mutual respect is a primary root cause of diagnostic error and
patient safety lapses. Collaboration is the structural framework upon which all 228
chapters of Buttaro’s collaborative practice are built.
Q2: The 2026 ADA Standards of Care have revised the criteria for obesity management in
patients with Type 2 Diabetes. For a patient currently at a Body Mass Index (BMI) of 33,
what is the specific weight loss target recommended to trigger significant metabolic
improvement and potential disease remission? A) 2% to 3% of baseline body weight. B) At
least 5% to 7% of baseline body weight. C) A minimum of 20% of baseline body weight before
pharmacological intervention. D) Returning to a "normal" BMI of 24.9 within the first six months
of diagnosis.
● The Answer: B) At least 5% to 7% of baseline body weight.
● Distractor Analysis: Option A is insufficient to achieve the physiological shifts in insulin
sensitivity required by the 2026 standards. Option C represents a legacy
"lifestyle-first-only" delay that the current standards have replaced with early, aggressive
pharmacotherapy (e.g., GLP-1 RAs). Option D is often clinically unattainable and focuses
on the "number" rather than the metabolic "function," which can lead to patient attrition
and psychological distress.
● The Mentor's Analysis: The 2026/2027 professional standard has moved away from the
"all-or-nothing" BMI approach toward incremental, evidence-based targets. A 5–7%
reduction is the "Hard Deck" for preventing the progression of pre-diabetes and improving
glycemic control in established Type 2 Diabetes. This reflects a shift in clinical register: we
no longer "encourage weight loss" generically; we "prescribe metabolic targets" with the
same precision as a statin or an ACE inhibitor.
Q3: A primary care coordinator is reviewing the 2026 CPT code updates for digital health.
Under the new guidelines, which code pair is used to report remote monitoring treatment
management when the clinical staff spends at least 10 minutes (but less than 20) during a
calendar month? A) 99457 and 99458. B) 99445 and 99470. C) 99213 and 99214. D) 98000
and 98008.
● The Answer: B) 99445 and 99470.
● Distractor Analysis: Option A refers to the legacy threshold of 20 minutes, which is now
considered "high-intensity" management. Option C contains standard E/M codes for
in-person visits. Option D refers to the new synchronous audio-video and audio-only
codes for telehealth encounters, not the longitudinal management of remote data.
● The Mentor's Analysis: The 2026 reduction of the management threshold from 20 to 10
minutes is a strategic pivot by CMS to reward "micro-interventions." As a professional,
you must understand that AI-augmented workflows allow your team to identify abnormal
heart rhythms or glucose spikes in seconds. If the billing structure stayed at 20 minutes, it
would penalize efficiency. Mastery of 99445/99470 allows your practice to remain
financially viable while providing the "continuous, preventive engagement" required to
, meet the 2027 standards for population health.
Q4: When calculating the estimated glomerular filtration rate (eGFR) for a 52-year-old
Black male patient presenting for his annual physical in 2027, which clinical protocol is
mandated by the NKF-ASN Task Force to ensure health equity? A) Use of the 2009 MDRD
equation with the race coefficient to avoid under-diagnosing. B) Use of the 2021 CKD-EPI
creatinine equation without a race coefficient. C) Exclusive use of the Cockcroft-Gault formula
for all drug dosing. D) Calculating eGFR based solely on the patient’s self-reported skin tone.
● The Answer: B) Use of the 2021 CKD-EPI creatinine equation without a race coefficient.
● Distractor Analysis: Option A is the "trap" of outdated practice; using a race coefficient
can falsely elevate eGFR results for Black patients, potentially delaying their referral for
kidney transplants or specialist care. Option C is used for some pharmacokinetic
modeling but is not the standard for staging chronic kidney disease (CKD). Option D is an
ethical and clinical absurdity that violates the "Island Rule" of biological precision.
● The Mentor's Analysis: The transition to race-free eGFR (CKD-EPI 2021) is a
non-negotiable professional standard in 2027. Race is a social, not a biological, construct.
By removing the coefficient, we ensure that every patient—regardless of ancestry—is
measured by the same metabolic yardstick. If the result is between 45 and 59
mL/min/1.73m² (Stage 3a), your next professional intuition should be to order a Cystatin C
test to calculate the eGFRcr-cys, which provides the highest level of accuracy for clinical
staging.
Q5: A patient with acute-onset low back pain presents to the clinic. The practitioner
identifies "saddle anesthesia" and new-onset urinary incontinence. According to the
Mahan Buttaro "Red Flag" highlights, what is the immediate required course of action?
A) Prescribe a 10-day course of high-dose NSAIDs and a muscle relaxant. B) Schedule an
outpatient MRI to be completed within the next 14 days. C) Initiate an "Emergency Referral" to
the nearest trauma center for suspected Cauda Equina Syndrome. D) Recommend bed rest
and a follow-up appointment in one month.
● The Answer: C) Initiate an "Emergency Referral" to the nearest trauma center for
suspected Cauda Equina Syndrome.
● Distractor Analysis: Option A treats the symptoms while ignoring a surgical emergency.
Option B is a dangerous delay; Cauda Equina requires intervention within hours, not
weeks, to prevent permanent paralysis. Option D is clinical negligence that would result in
a devastating professional crisis.
● The Mentor's Analysis: The "Red Flag" highlights in Buttaro's 6th and 7th editions are
"Not-to-be-Missed" signals. In the interprofessional environment, these are the triggers
that bypass the standard "wait-and-see" protocols. Professional intuition dictates that
when neurological function (bowel/bladder) is compromised, the primary care role shifts
from "Diagnostician" to "Emergency Coordinator." Your success as a Lead Practitioner is
defined as much by what you refer as what you treat.
Q6: In the 2026 ADA Standards of Care, the classification of MASLD (Metabolic
Dysfunction-Associated Steatotic Liver Disease) has been integrated into the diabetic
management algorithm. Which medication class is now preferred for glycemic
management in a patient with Type 2 Diabetes and biopsy-proven MASH (Metabolic
Dysfunction-Associated Steatohepatitis)? A) Sulfonylureas such as Glimepiride. B) GLP-1
Receptor Agonists (GLP-1 RAs) with demonstrated benefit. C) DPP-4 Inhibitors such as
Sitagliptin. D) Meglitinides.
● The Answer: B) GLP-1 Receptor Agonists (GLP-1 RAs) with demonstrated benefit.
● Distractor Analysis: Option A is weight-neutral or causes weight gain, providing no
